Department of Internal Medicine, Division of Gastroenterology, New York Methodist Hospital, Weill Cornell Medical College, Brooklyn, NY 11215, United States.
World J Gastroenterol. 2012 Aug 28;18(32):4350-6. doi: 10.3748/wjg.v18.i32.4350.
To examine effects of chronic methadone usage on bowel visualization, preparation, and repeat colonoscopy.
In-patient colonoscopy reports from October, 2004 to May, 2009 for methadone dependent (MD) patients were retrospectively evaluated and compared to matched opioid naive controls (C). Strict criteria were applied to exclude patients with risk factors known to cause constipation or gastric dysmotility. Colonoscopy reports of all eligible patients were analyzed for degree of bowel visualization, assessment of bowel preparation (good, fair, or poor), and whether a repeat colonoscopy was required. Bowel visualization was scored on a 4 point scale based on multiple prior studies: excellent = 1, good = 2, fair = 3, or poor = 4. Analysis of variance (ANOVA) and Pearson χ(2) test were used for data analyses. Subgroup analysis included correlation between methadone dose and colonoscopy outcomes. All variables significantly differing between MD and C groups were included in both univariate and multivariate logistic regression analyses. P values were two sided, and < 0.05 were considered statistically significant.
After applying exclusionary criteria, a total of 178 MD patients and 115 C patients underwent a colonoscopy during the designated study period. A total of 67 colonoscopy reports for MD patients and 72 for C were included for data analysis. Age and gender matched controls were randomly selected from this population to serve as controls in a numerically comparable group. The average age for MD patients was 52.2 ± 9.2 years (range: 32-72 years) years compared to 54.6 ± 15.5 years (range: 20-81 years) for C (P = 0.27). Sixty nine percent of patients in MD and 65% in C group were males (P = 0.67). When evaluating colonoscopy reports for bowel visualization, MD patients had significantly greater percentage of solid stool (i.e., poor visualization) compared to C (40.3% vs 6.9%, P < 0.001). Poor bowel preparation (35.8% vs 9.7%, P < 0.001) and need for repeat colonoscopy (32.8% vs 12.5%, P = 0.004) were significantly higher in MD group compared to C, respectively. Under univariate analysis, factors significantly associated with MD group were presence of fecal particulate [odds ratio (OR), 3.89, 95% CI: 1.33-11.36, P = 0.01] and solid stool (OR, 13.5, 95% CI: 4.21-43.31, P < 0.001). Fair (OR, 3.82, 95% CI: 1.63-8.96, P = 0.002) and poor (OR, 8.10, 95% CI: 3.05-21.56, P < 0.001) assessment of bowel preparation were more likely to be associated with MD patients. Requirement for repeat colonoscopy was also significant higher in MD group (OR, 3.42, 95% CI: 1.44-8.13, P = 0.01). In the multivariate analyses, the only variable independently associated with MD group was presence of solid stool (OR, 7.77, 95% CI: 1.66-36.47, P = 0.01). Subgroup analysis demonstrated a general trend towards poorer bowel visualization with higher methadone dosage. ANOVA analysis demonstrated that mean methadone dose associated with presence of solid stool (poor visualization) was significantly higher compared to mean dosage for clean colon (excellent visualization, P = 0.02) or for those with liquid stool only (good visualization, P = 0.01).
Methadone dependence is a risk factor for poor bowel visualization and leads to more repeat colonoscopies. More aggressive bowel preparation may be needed in MD patients.
研究慢性美沙酮使用对肠道可视化、准备和重复结肠镜检查的影响。
回顾性评估 2004 年 10 月至 2009 年 5 月因美沙酮依赖(MD)患者的住院结肠镜检查报告,并与匹配的阿片类药物未使用对照组(C)进行比较。应用严格标准排除已知引起便秘或胃动力障碍的危险因素的患者。对所有符合条件的患者的结肠镜检查报告进行肠道可视化程度、肠道准备评估(良好、中等或差)和是否需要重复结肠镜检查的分析。肠道可视化程度根据多项既往研究进行 4 分制评分:优秀=1,良好=2,中等=3,差=4。采用方差分析(ANOVA)和 Pearson χ²检验进行数据分析。亚组分析包括美沙酮剂量与结肠镜检查结果的相关性。MD 组和 C 组之间差异有统计学意义的所有变量均纳入单变量和多变量逻辑回归分析。双侧 P 值<0.05 被认为具有统计学意义。
应用排除标准后,共有 178 例 MD 患者和 115 例 C 患者在指定研究期间接受了结肠镜检查。共有 67 份 MD 患者和 72 份 C 患者的结肠镜检查报告纳入数据分析。从该人群中随机选择年龄和性别匹配的对照组作为对照组,在数量上具有可比性。MD 患者的平均年龄为 52.2±9.2 岁(范围:32-72 岁),C 组为 54.6±15.5 岁(范围:20-81 岁)(P=0.27)。MD 组和 C 组中分别有 69%和 65%的患者为男性(P=0.67)。评估结肠镜检查报告的肠道可视化时,MD 患者的固体粪便比例(即较差的可视化)明显高于 C 组(40.3%比 6.9%,P<0.001)。MD 组较差的肠道准备(35.8%比 9.7%,P<0.001)和需要重复结肠镜检查(32.8%比 12.5%,P=0.004)的比例明显高于 C 组。单因素分析显示,与 MD 组相关的因素为粪便颗粒存在(比值比[OR],3.89,95%可信区间:1.33-11.36,P=0.01)和存在固体粪便(OR,13.5,95%可信区间:4.21-43.31,P<0.001)。肠道准备的中等(OR,3.82,95%可信区间:1.63-8.96,P=0.002)和较差(OR,8.10,95%可信区间:3.05-21.56,P<0.001)评估更可能与 MD 患者相关。MD 组需要重复结肠镜检查的比例也明显更高(OR,3.42,95%可信区间:1.44-8.13,P=0.01)。多因素分析显示,唯一与 MD 组相关的变量是存在固体粪便(OR,7.77,95%可信区间:1.66-36.47,P=0.01)。亚组分析显示,美沙酮剂量越高,肠道可视化越差。ANOVA 分析表明,与清洁结肠(优秀可视化)或仅存在液体粪便(良好可视化)相比,与存在固体粪便(较差可视化)相关的美沙酮剂量的平均剂量显著更高(P=0.02)。
美沙酮依赖是肠道可视化不良和导致更多重复结肠镜检查的危险因素。MD 患者可能需要更积极的肠道准备。